Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis
Multiple Sclerosis Journal · 2025
DOI: 10.1177/13524585251361330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2025. Verfasst von Franziska Axhausen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Giessen, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ocrelizumab (OCR) and ofatumumab (OFA)are approved and their differences in dosing route and interval allow personalized treatment. However, there are no data on whether lateral switches between both substances affect treatment effectiveness or safety.
Methods
We screened our local cohort of MS patients, who began OCR since 09/2020 or OFA since 09/2021. Patients with a lateral switch were matched to controls who continuously received initial B-cell depleting therapy (BCT). We compared disease courses including effectiveness outcomes as well as peripheral CD19+ B-cell counts and serum IgG levels.
Results
From 09/2020 to 03/2024, 713 patients were subjected to BCT (OCR: 396; OFA: 317 [as in Fig.1]). The matched OCR cohort included 38 switchers and 149 controls. The OFA cohort consisted of 24 switchers and 83 controls. Effectiveness outcomes were comparable among switchers and controls. B cell depletion appeared slightly pronounced following a switch. Serum IgG levels declined faster among switchers compared to controls (OCR: 9.7 vs 9.0 g/L; p = 0.007 ; manifest hypogammaglobulinemia (HGG) in 13.2% vs 6.0%; OFA: 9.7 vs 8.4 g/L; p = 0.016 ; manifest HGG in 8.3% vs 2.4%).
Conclusions
Lateral switching between BCT does not abate effectiveness in this matched real-world cohort. Our observation of increased loss of IgG warrants further validation, but may indicate niche-specific immunological effects of OFA and OCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Giessen, Germany.
- Department of Neurology, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Dusseldorf, Germany.
- Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.
ORCID-Profile: Pauline Mühlenbrock, Steffen Pfeuffer
Zitieren
APA
Axhausen, F., Mrochen, A., Winter, P., Baumgart, R., Mühlenbrock, P., Mück, A., Wolff, S., Meuth, S. G., Möllenhoff, K., & Pfeuffer, S. (2025). Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585251361330
Vancouver
Axhausen F, Mrochen A, Winter P, Baumgart R, Mühlenbrock P, Mück A, et al. Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis. Multiple Sclerosis Journal. 2025. doi:10.1177/13524585251361330
BibTeX
@article{Axhausen2025,
author = {Axhausen, Franziska and Mrochen, Anne and Winter, Pia and Baumgart, Romy and Mühlenbrock, Pauline and Mück, Anna and Wolff, Stephanie and Meuth, Sven G and Möllenhoff, Kathrin and Pfeuffer, Steffen},
title = {Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis},
journal = {Multiple Sclerosis Journal},
year = {2025},
doi = {10.1177/13524585251361330}
}
EUVIMED